The extracellular activities of the human immunodeficiency virus (HIV) transactivator protein (Tat) include induction of angiogenesis and stimulation of monocyte migration. Here it is shown that polymorphonuclear leukocytes (PMNL), mostly neutrophils, rapidly invade in response to Tat in vivo and initiate the formation of new vessels. In vitro, Tat was chemotactic for PMNL and induced calcium (Ca 2+ ) mobilization. Tat proteins with inactivating substitutions in the arginine-glycine-aspartic acid or basic domain were still active in inducing PMNL migration, whereas Tat peptides mapped the migration and Ca 2+ mobilization activity to a cysteine-rich core domain, previously described as a Tat "chemokine-like" region (peptide CysL ). Tat and the CysL 24-51 peptide also induced PMNL superoxide production and the release of the angiogenic factors interleukin-8 and vascular endothelial growth factor from PMNL. CysL 24-51 did not induce endothelial cell migration but was angiogenic in vivo. These data indicate that the Tat activity on PMNL is mediated by its chemokine-like region and that PMNL recruitment by Tat is linked to angiogenesis.
genesis by binding to, and activating, the vascular endothelial growth factor (VEGF) receptor, KDR [12] [13] [14] . The extracellular activity of Tat appears to affect the pathological process of HIV infection and AIDS, and data suggest that a humoral response to this molecule could slow the progression of the disease (reviewed in [21] ).
Several groups have shown that Tat is chemotactic for human monocytes [22] [23] [24] [25] [26] . Although both the arginine-glycineaspartic acid (RGD) [22] and basic [24] domains of Tat have been suggested to be involved, the chemotactic activity induced by the Tat basic or RGD domain was weak for monocytes [25] . The majority of the monocyte chemotactic activity of Tat localizes to the cysteine-rich and core regions of Tat [26] . These regions of Tat show a limited sequence similarity with chemokines, and we have demonstrated that Tat induces G i protein-mediated calcium fluxes [27] . Cross-desensitization experiments and ligand-binding competition studies on monocytes and receptor transfected cells indicate that Tat binds to certain b-chemokine receptors with high affinity [27] . However, lack of complete desensitization of the Tat response by these b-chemokines suggests that Tat interacts with other G protein-coupled receptors as well; recent studies indicate that Tat also binds and activates the a-chemokine receptor CXCR4 on monocytes and lymphocytes [28] .
Tat has been shown to induce a rapid neutrophil infiltration in a rat model of AIDS dementia [29] . We observed a strong neutrophil infiltration into Matrigel sponges (Becton Dickinson, Bedford, MA) containing Tat in murine models. In these models, the infiltrating polymorphonuclear leukocytes (PMNL) appear to be the first cells recruited toward the Tat stimulus, whereas macrophages and other effector cells (lymphocytes or endothelial cells) appear later. PMNL are known to produce angiogenic factors after some stimuli [30, 31] , which could further contribute to the angiogenic response. These observations raise the possibility that Tat could act as a chemoattractant for PMNL, which, in turn, could contribute to neovascularization.
PMNL show an abnormal behavior in HIV infection; most studies indicate that neutrophils are in a primed state during the asymptomatic phase, with normal CD4 ϩ counts; however these phagocytes become "indolent" with progression to clinically manifested AIDS [32] [33] [34] . The hyperactivity of PMNL in HIV-infected individuals appears to lead to increased production of inflammatory cytokines and amplification of reactive oxygen species production. The consequence may be an enhancement of systemic immune cell activation favoring HIV infection, a general oxidative stress [35] , and eventual loss of PMNL effectiveness, which contribute to the opportunistic infections often observed in AIDS patients.
We have studied the effect of extracellular Tat on PMNL, testing induction of migration, Ca 2ϩ mobilization, superoxide production, and release of VEGF and interleukin (IL)-8 by Tat-treated PMNL. We also aimed to identify the region of Tat involved in this activity and to determine whether this region, although not active on endothelial cells in vitro, is angiogenic in vivo.
Materials and Methods
Proteins and peptides. Lipopolysaccharide (LPS)-free Tat protein (both 1-86 and 1-101 variants) and Tat peptides covering amino acids 1-24, 24-51, 24-51mut (CCFrSSG), and 79-101 were synthesized by Tecnogen (Caserta, Italy), purified by high-performance liquid chromatography, and quality controlled by mass spectroscopy. Tat peptides for amino acids 46-60, 56-70, and 65-80 were purchased from Technogenetics (London). Recombinant GST-Tat and GST-Tat mutants (RGD mutations R78K and D80E; basic mutations R49G, K50I, R52L, and R53I) have been described elsewhere [36] . Tat peptides and the full-length proteins were dissolved in PBS containing 0.1% bovine serum albumin (BSA; highly purified, with low levels of fatty acids [Sigma, Milan, Italy]) and 10 mM dithiothreitol (Sigma) and were stored at Ϫ80ЊC. Recombinant IL-8 (kindly provided by Sandoz Corp., Vienna, and Dr. A. Proudfoot, Ares-Serono, Geneva) and the chemokine stromal-derived factor (SDF)-1a (Peprotech, London) were used as positive controls.
The Matrigel sponge model and electron microscopy. The Matrigel sponge model of angiogenesis, introduced by Passaniti et al. [37] and modified by Albini et al. [15] , was used. Tat (2 nM) or Tat peptides (10 nM) and heparin (20 U/mL) were mixed with unpolymerized liquid Matrigel (commercially available from Becton Dickinson) at 4ЊC to a final volume of 600 mL, then injected subcutaneously into the flank of C57/bl6 male mice, where it quickly polymerized. Matrigel with buffer alone was used as negative control. Four days later, the gels were collected, weighed, and processed for electron microscopy. Gels loaded with Tat peptides were also routinely embedded in paraffin, for the microscopic observation of PMNL, or were used for hemoglobin quantification.
Hemoglobin content was determined by the Sigma Drabkin solution kit 525. The Matrigel pellets were weighed and were minced in 1 mL of distilled water; after centrifugation (13,000 g for 5 min), 200 mL of each sample was diluted in 800 mL of Drabkin solution. A standard hemoglobin solution was used to prepare a titration curve. Samples were measured spectrophotometrically at 540 nm.
In preparation for electron microscopy, samples were fixed with 2.5% glutaraldehyde (Polyscience, Warrington, PA) in 0.1 M cacodylate buffer, pH 7.3, and were postfixed with 1% OsO 4 (Polyscience) in the same buffer. After en bloc staining with 1% uranyl acetate and dehydration with ethanol and propylene oxide, samples were embedded in LX112 (Polyscience). Grey-silver sections were stained with uranyl acetate and lead citrate and were observed with Zeiss (Oberkochen, Germany) EM 10C or EM 902 electron microscopes.
Purification of PMNL. Freshly prepared buffy coats were diluted 1:3 in PBS and were centrifuged at 180 g for 10 min 3 times to reduce contamination by platelets. After a further dilution in PBS, cells were layered on ficoll-hypaque density gradient (Seromed, Berlin) and were centrifuged at 280 g for 30 min. PBMC were collected at the interface, and PBS and residual ficoll-hypaque were removed. The pellet, which contained erythrocytes and PMNL leukocytes, was diluted with 3 volumes of ammonium chloride lysis solution (NH 4 Cl, 155 mM; KHCO 3 , 10 mM; and EDTA, 0.1 mM, at pH 7.4) and was incubated at 4ЊC for 10 min. After centrifugation (180 g for 10 min, at 4ЊC) the lysis was repeated to eliminate residual erythrocytes. The final pellet, assessed by direct observation of nuclear morphology to consist of 196% PMNL, was immediately used for chemotaxis or Ca 2ϩ mobilization assays, after dilution in the proper buffer solution. Random PMNL preparations were also examined by flow cytometry to control for their quality; in all cases, purity was always 196%.
Chemotaxis assays. Chemotaxis was performed according to the methods of Falk et al. [38] , in 48-microwell chemotaxis chambers (Costar-Nucleopore, Milan, Italy), using 5-mm pore-size polyvinylpyrrolidone-free polycarbonate filters (Costar-Nucleopore). The lower compartment of each chamber was filled with 27 mL of chemoattractant diluted in RPMI-0.1% BSA. Simple RPMI-0.1% BSA (serum-free medium) was used as the control for unstimulated random migration. Each well of the upper compartment was filled with 50 mL of PMNL suspension in RPMI-0.1% BSA ( 6 5 ϫ 10 cells/mL), and each experimental procedure was performed in sestuplicate. The filled chambers were incubated at 37ЊC in a 5% CO 2 humidified atmosphere for 45 minutes. The filters were then removed, and the cells were fixed with 100% ethanol and stained with toluidine blue. Cells that had not migrated were removed from the upper surface of the filter, using filter paper. Migrated cells were counted by scanning the filter surface, followed by densitometry analysis of cell migration in each well by use of the National Institutes of Health Image Analysis program, as described elsewhere [27] . On microscopic examination, all migrated cells showed the distinct PMNL morphology.
Calcium flux assays. For calcium flux assays, cells were labeled with Fura2-AM (ICN, Milan, Italy), and the Ca 2ϩ mobilized in response to the stimuli was measured in a fluorimeter (PerkinElmer, Pomona, CA) [27] . Briefly, freshly prepared PMNL were washed with calcium buffer (125 mM NaCl, 5 mM KCl, 1 mM Na 2 HPO 4 , 1 g/L glucose, 25 mM Hepes, 1 mM CaCl 2 , and 0.5 mM MgCl 2 ) containing 0.1% BSA, resuspended in the same buffer, and loaded with 1 mg/mL of Fura2-AM (ICN) for 30 min at 37ЊC. Cells were then washed twice with calcium buffer without BSA, and the cell pellet was resuspended at cells/100 mL. 6 5 ϫ 10 For the determination of free Ca 2ϩ cytoplasmic concentration, cells for each sample were monitored at 37ЊC with an 6 2.5 ϫ 10 LS5 spectrofluorimeter (Perkin-Elmer) equipped with a thermostatically controlled cuvette holder and a stirring apparatus. Stimuli were added to the cell suspension (in a volume never exceeding 1% of the 1.5-mL final volume), using equimolar amounts of peptides. The excitation wavelength was 346 nm, and fluorescence was measured at 496 nm. The Ca 2ϩ mobilized was calculated by the method of Grynkiewicz et al. [39] .
Quantitation of VEGF and IL-8 production. Immediately after purification, the highly purified granulocytes (199.5% pure, as assessed by morphology, and containing !3%-4% eosinophils, as revealed by MayGrunwald-Giemsa staining) were suspended in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS; LPS !0.009 ng/mL; Seromed, Biochrom KG, Berlin) and were treated either with Tat or with Tat peptides (CysL , CysL 24-51mut , or Pep ), at final concentrations of 100-500 nM, or with tumor necrosis factor-a (5 ng/mL). The PMNL suspension ( / 6 3.5 ϫ 10 mL) was plated in 24-well tissue culture plates (Nunc, Roskilde, Denmark) and incubated at 37Њ C in 5% CO 2 for р21 h. At the time points indicated in the Results section, cell-free supernatants were harvested and were stored at 20ЊC.
The VEGF concentration was measured in cell-free supernatants, using a specific ELISA (12 pg/mL detection limit), purchased from R&D Systems (Minneapolis), according to the manufacturer's instructions but with minor modifications. Briefly, flat-bottomed 96-well plates (MaxiSorp, Nunc) were coated with 50 mL/well of 1 mg/ mL polyclonal anti-human VEGF antibody (AF293NA; R&D Systems) in PBS and were incubated overnight. After 4 washings with PBS 0.05% Tween 20 (washing buffer), 150 mL/well of blocking buffer (PBS-1% BSA, 5% sucrose, and 0.05% NaN 3 ) was added to the plates and incubated for 1 h. Plates were then rinsed with washing buffer, after which 50 mL/well of either VEGF standards (30-960 pg/mL diluted in RPMI 1640 with 10% FCS) or PMNL supernatants was added and was incubated for 2 h. The plates were subsequently washed, and 50 mL/well of a 0.5 mg/mL biotinylated anti-human VEGF antibody (BAF293; R&D Systems) solution in Tris-buffered saline (TBS), containing 0.1% BSA and 0.05% Tween 20, was added. After another 2 h of incubation, the plates were washed, and 50 mL/well of a 1:10,000 dilution of streptavidinconjugated alkaline phosphatase (Life Technologies, Rockville, MD) solution was added and was incubated for 1 h. The plates were then washed with TBS with 0.05% Tween 20, at pH 7.4, and a chromogenic reaction was performed by using the ELISA amplification system (Life Technologies). The reaction was stopped with 0.3 M H 2 SO 4 , and the adsorbance was measured at 490 nM. IL-8 was measured in the cell-free supernatants, using a doubleligand ELISA method, as described elsewhere [40] . 2 ϫ 10 2 ϫ 10 phils/s) [42] .
Statistical methods. Statistical analysis was performed using Student's t test, to compare raw counts obtained from each sample with proper controls (mainly negative controls).
Results

PMNL invasion in response to Tat in vivo.
After subcutaneous injection, Matrigel rapidly formed a gel that was stable and, in the absence of additional factors, was poorly infiltrated by host cells. In contrast, Matrigel implanted along with HIV Tat and heparin became strongly vascularized after 4 days [15] . The angiogenic process induced by Tat was associated with the ability to recruit PMNL. Electron microscopy of the Tat/heparin containing Matrigel sponges 4 days after injection into C57/bl6 male mice showed a massive infiltration of PMNL (figure 1). Neutrophils were frequently detected along clefts in the gel, sometimes in clusters, and often they appeared to lead the other invading cells and red blood cells ( figure 1) . Most of the neutrophils were degranulating, similar to the degranulation observed when Kaposi's sarcoma cell supernatants were used [15] .
Induction by Tat of PMNL chemotaxis and calcium mobilization.
The high content of neutrophils in the Matrigel sponges in vivo suggested that Tat might act as a direct chemotactic factor for these cells. In vitro, the full-length 1-101 amino acid HIV-1 Tat protein induced a strong, dose-dependent migration of purified PMNL, beginning at doses as low as 0.32 nM ( figure 2A ). Checkerboard analysis of Tat-induced migration showed a chemotactic response with a chemokinetic component (data not shown). PMNL showed a similar strong chemotactic response to the control chemokine IL-8 ( figure 2A ), known to act on neutrophils, at doses comparable to those of Tat.
Chemokine receptor stimulation causes a rapid and transient increase of cytoplasmic Ca 2ϩ . Tat (40 nM) induced a Ca 2ϩ flux in PMNL similar to that induced by chemokine IL-8 ( figure  2B ) or SDF-1a (not shown) at the same concentrations (40 nM). The ability of Tat to induce a Ca 2ϩ flux was completely blocked by the addition of specific anti-Tat monoclonal antibodies [43] , which had no effect on the response to IL-8 ( figure  2B ). These data suggest that induction of PMNL migration and Ca 2ϩ mobility are closely correlated and are due to the Tat protein and that the response of PMNL to Tat may be mediated by Ca 2ϩ as a second messenger. To determine the possible contribution of the basic and RGD domains of Tat to PMNL chemotaxis, we tested 2 Tat proteins in which either the basic domain (R49G, K50I, R52L, or R53I) or the RGD sequence (R78K or D80E) was inactivated by the substitutions indicated [36] . Both of these mutant proteins showed chemotactic activity similar to that of wild-type Tat protein ( figure 3A) , indicating that neither of these domains was involved in PMNL chemotaxis. A series of overlapping peptides covering the entire Tat protein sequence was used in equimolar (10 Ϫ6 M) concentrations as chemoattractants, to test the involvement of other functional regions of Tat [26, 27] in PMNL migration ( figure 3B ). These Tat peptides included the NH-terminus (Pep ), the cysteine and core regions (CysL ), the basic domain (basic [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] ), a peptide between the basic and RGD regions (Pep [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] ), the RGD domain (RGD [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] ), and the COOH-terminus (Pep ). The peptide encompassing the cysteine-rich and core domains (CysL ) proved to be the only peptide to be able to induce a strong, dose-dependent, and reproducible PMNL migration (figure 3B, 3C) and calcium signaling ( figure 3D ). The RGD peptide only induced a minor change in the steady-state of intracellular calcium concentration. The NH-and COOHterminal peptides and the peptide between the basic and RGD regions were inactive (figure 3B), whereas the basic and the RGD peptides occasionally showed minimal activity on PMNL from some blood donors. The CysL 24-51mut peptide, with a CCFrSSG substitution (CysL 24-51mut ) that is critical for chemokine activity [27] , showed a dramatic loss of chemotactic activity in comparison with equimolar wild-type peptide ( figure 3C ). This peptide also showed loss of the ability to activate calcium fluxes ( figure  3D ). These data indicate that induction of PMNL migration and Ca 2ϩ mobilization are closely correlated and are dependent on the cysteine-core domain of Tat, which has previously been shown to harbor chemokine-like activity [27] .
VEGF and IL-8 release. PMNL appear to be rapidly recruited in response to Tat in the in vivo Matrigel gel model of angiogenesis (figure 1). These cells migrate before the endothelial cells and appear to be leading vascular cell recruitment. PMNL have been shown to release both VEGF and IL-8 [30, 44] , suggesting that release of these factors by PMNL in response to Tat could further contribute to the Tat-induced angiogenic response. PMNL were treated with Tat or Tat peptides (CysL , CysL 24-51mut and Pep ), and the production and release of VEGF and IL-8 in the supernatants were measured over time.
Tat induced a significant release of both VEGF and IL-8, with the maximum response observed after 5 h (figure 4). Tat evoked a 3-fold increase over untreated controls in the yield of VEGF recovered from PMNL supernatants (figure 4), which remained high р21 h, with maximal differences noticed at 5 h. The CysL peptide was also able to induce VEGF release, whereas the CysL 24-51mut and Pep 79-101 peptides were inactive ( figure 4, inset) . IL-8 release by Tat-stimulated PMNL after 5 h was 15-fold higher than that of untreated controls ( figure 4) . At 21 h, the levels of IL-8 were decreased. The CysL 24-51 peptide induced IL-8 release with kinetics similar to those of Tat, whereas the CysL 24-51mut and Pep 79-101 were inactive (figure 4, inset). Control PBMC preparations from the same donors did not show any VEGF release, in accord with previous data [45] .
Superoxide anion (O 2 Ϫ ) release. Because stimulation of chemokine receptors leads to "respiratory burst" activation in human neutrophils [46] , we investigated whether PMNL produce superoxide anion (O 2 Ϫ ) in response to Tat and Tat peptides. Tat induced a significant increase in superoxide anion production (figure 5), with amounts similar to those induced by chemokines SDF-1a or IL-8 after 2 min of stimulation. After 2 min, the O 2 Ϫ concentration was still elevated in Tat-treated samples, whereas it rapidly decreased in the presence of SDF-1a or IL-8.
The CysL 24-51 peptide was also able to induce O 2 Ϫ production, whereas CysL 24-51mut and Pep 79-101 peptides had no effect ( figure   5 , inset). CysL 24-51 peptide maintained high superoxide production for several minutes, similar to that observed for Tat.
Angiogenic activity of the chemokine-like CysL Tat peptide. The CysL peptide lacks the basic domain of Tat, shown to bind and activate KDR [12] , and the integrin-binding RGD domain [8] [9] [10] , which is active on endothelial cells. However, this domain does contain the chemokine-like domain of Tat active on monocytes [26, 27] and, as shown above, on PMNL. As expected for a peptide lacking the basic and RGD domains, the CysL 24-51 peptide did not induce endothelial cell migration (data not shown). However, inclusion of this peptide in Matrigel did induce a strong angiogenic response in vivo (table 1) . The CysL 24-51mut peptide, identical to the CysL peptide but with an SSG substitution of the CCF motif, which inactivates its ability to induce PMNL migration and Ca 2ϩ fluxes, did not induce angiogenesis (table 1) . A strong PMNL infiltrate was observed in gels containing the CysL 24-51 peptide, whereas no PMNL infiltration was detected in control gels (not shown) or in Matrigel containing the heparin-binding growth factor bFGF [15] , which has a size and charge similar to those of Tat. These data indicate that a peptide that is not directly active on endothelial cells but has significant activity on PMNL and monocytes [26, 27] is capable of inducing an angiogenic response, presumably through recruitment and activation of these mediators of angiogenesis.
Discussion
In addition to its principal transactivating activity [47] , Tat protein also appears to be released into the extracellular milieu (for review, see [2] ), where extensive evidence suggests that it acts as a cytokine. One of the cytokine-like activities of Tat is its angiogenic activity, and Tat is considered to be a cofactor for AIDS-associated Kaposi's sarcoma. In a model of Tat-induced angiogenesis in vivo, we observed an infiltration of PMNL that appeared to precede endothelial cell and macrophage migration (figure 1). Tat-induced migration has been reported for endothelial cells [18] , monocytes [22] , dendritic cells [25] , and B-cells [48] . Here we show for the first time that Tat induces a dosedependent PMNL migration in vitro with a chemotactic potential comparable to that of IL-8, at nM concentrations similar to those shown to induce angiogenesis in vivo [15] . Tat also induced rapid Several studies have shown that macrophages can release factors that are angiogenic, including VEGF, considered one of the key angiogenic factors in development and tumorigenesis, and the angiogenic chemokine IL-8. Activated PMNL have also been demonstrated to release VEGF and IL-8 [30, 31] . A similar activation by Tat could further contribute to the angiogenic activity of Tat, as suggested by electron microscopy of Tat-containing Matrigel sponges implanted in vivo, in which neutrophils are often at the leading tip of clefts and are followed by other invading cells. Our data indicate that PMNL could participate in the angiogenic process induced in Matrigel sponges, in turn attracting macrophages and vascular cells. This hypothesis is further supported by in vivo observations ob- Tat induced a sustained increase in VEGF secretion, in comparison with that in untreated controls. Tat also induced secretion of IL-8, which peaked after 5 h (15-fold higher than the level in untreated controls) and declined soon after. The CysL peptide was able to exert the same activity, whereas the CysL 24-51mut peptide was ineffective (insets; Tat and Tat peptides were tested in the same experiments but were plotted separately for clarity). Values shown are of mean ‫ע‬ SE 3 different tests. The differences between Tat-treated and control PMNL were significant for both VEGF and IL-8 release ( ) at P ! .01 5 h. Human immunodeficiency virus transactivator protein (Tat), interleukin (IL)-8, and stromal-derived factor (SDF)-1a (Peprotech, London) induced similar early responses at 2 min, but, whereas IL-8 and SDF-1a superoxide production decreased rapidly, Tat superoxide production was stable for 110 min. The CysL peptide was able to exert the same activity, whereas the CysL 24-51mut peptide had no effect. Concentrations of both 100 and 500 nM were used, with similar results. Data shown are of triplicates of a representative of independent experiments. mean ‫ע‬ SD tained by using the CysL Tat peptide. This peptide, which lacks the RGD and basic domains that interact with intergrins or KDR on endothelial cells, is unable to induce endothelial cell migration in vitro (data not shown). However, the CysL peptide did induce an angiogenic response in vivo. The CysL peptide-induced angiogenesis was accompanied by PMNL infiltration and, presumably, infiltration by monocytes/macrophages, which could indirectly induce angiogenesis by endothelial cells as a result of Tat-stimulated release of angiogenic factors by these cells.
Here we demonstrate that Tat and its CysL peptide are able to induce the release of both IL-8 and VEGF by PMNL. Tat has been shown to induce IL-8 release from monocytes [49] , T cells [50] , and endothelial cells [51] , which suggests that this is a general activity of Tat.
Electron microscopy showed that the PMNL invading in response to Tat in vivo were frequently degranulating, indicating an activated state. The observation that Tat induces PMNL activation and superoxide anion production could represent one of the mechanisms whereby granulocytes are found to be constitutively activated in AIDS patients [32] . On activation (0-2 min), the kinetics of superoxide production in PMNL stimulated with Tat or CysL 24-51 peptide were more sustained over time than were those induced by IL-8 or SDF1a. Tat-induced superoxide anions continued to be released for an extended period (observed up to 30 min), whereas chemokine stimulation induced superoxide anion release for only 4-6 min. This persistent activation could be linked to a promiscuous activation of different chemokine receptors by Tat, to relatively inefficient down-regulation of the receptor by Tat, or to binding to secondary receptors such as integrins. These data confirm our hypothesis that Tat is able to interact with chemokine receptors but is not a perfect mimic of any known chemokine, as may be expected for a viral product.
It has been shown that neutrophils of Tat-transgenic animals also have impaired function [52] , further supporting a role for Tat in alteration of PMNL activity in AIDS. The role of Tatinduced impairment of PMNL function in HIV infection and AIDS remains unclear, as these cells are not direct targets for viral infection. PMNL activation in AIDS patients might con-tribute to the cytokine imbalance that characterizes this syndrome [53] . The apparent suboptimal activation of PMNL is similar to that observed for T cells, in which extracellular Tat seems to induce a partial activation that enhances HIV infection and also favors entrance into anergy or apoptosis [54, 55] . Tat's effects on PMNL may contribute to the immune disregulation observed in HIV infection and progression to AIDS and could be a factor in the frequent opportunistic infections observed in AIDS patients.
Recent studies have shown that the high insurgence of Kaposi's sarcoma in AIDS patients is dependent on factors in addition to human herpesvirus 8 infection and immune suppression (reviewed in [56] ). Numerous studies have suggested that the multiple angiogenic activities of Tat may contribute to Kaposi's sarcoma, and it has recently been demonstrated that Kaposi's sarcoma tumors grow significantly more rapidly in Tat-transgenic animals [57] . These tumors were associated with a strong PMNL infiltrate, further suggesting that these cells may play an important role in the uncontrolled angiogenesis characteristic of Kaposi's sarcoma.
